Author

Marisa Kruidenier

University of Pennsylvania

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:metabolism & bioenergetics· 1 Approach:statistical model· 1

Frequent Co-Authors

A’ishah Bakayoko· 2 shared David A. FrumaniD· 2 shared Gerald B. W. WertheimiD· 2 shared Madhuri PauliD· 2 shared Martin P CarrolliD· 2 shared Roberta BuonoiD· 2 shared Saı̈d M. SebtiiD· 2 shared Sarah J. SkuliiD· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A’ishah Bakayoko

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia by depleting geranylgeranyl pyrophosphate

Roberta Buono, Dennis Juarez, Madhuri Paul, Sarah J. Skuli, Ian B. Wong, Ishita Tarnekar, Zhili Ying, Izabelle Le, Gerald B. W. Wertheim, A’ishah Bakayoko, Marisa Kruidenier, Saı̈d M. Sebti, Marina Konopleva, Angela G. Fleischman, Cholsoon Jang, , David A. Fruman

This study shows pitavastatin overcomes venetoclax resistance in AML by depleting GGPP, inducing apoptosis through PUMA upregulation and MCL-1 reduction, and suppressing mitochondrial metabolism.

bioRxiv · Oct 27, 2025 · PreprintCancer Biology

Chemoresistance of TP53 mutant AML requires the mevalonate byproduct, GGPP, for regulation of ROS and induction of a mitochondria stress response

Sarah J. Skuli, A’ishah Bakayoko, Marisa Kruidenier, Bryan Manning, Paige Pammer, Akmal Salimov, Owen Riley, Gisela Brake-Sillá, Derrick L. Dopkin, Michael Bowman, Leslie N. Martinez-Gutierrez, Colin C. Anderson, Julie A. Reisz, Roberta Buono, Madhuri Paul, , Martin P Carroll

This study identifies GGPP, a mevalonate pathway byproduct, as critical for chemoresistance in TP53mut AML through ROS regulation and mitochondria stress response, suggesting statin-based therapies could be effective.

Leukemia · Jul 9, 2025Peer-reviewedCancer Biology